Thrombotech Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

Thrombotech General Information

Description

Developer of THR-18, a peptide derived from Plasminogen Activator Inhibitor-1, which is administered with tissue plasminogen activator alongside existing stroke treatments. The company's THR-18 focuses on the treatment of acute ischemic stroke, as well as against heart attacks, neurodegenerative diseases, lung embolisms, occluded arteries and veins in the legs and arms and traumatic brain injuries resulting from road accidents, falls and other incidents.

Contact Information

Website
www.thrombotech.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 9 Hamazmera Street
  • Ness Ziona 74047
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
D-Pharm
Corporate Office
  • 9 Hamazmera Street
  • Ness Ziona 74047
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Thrombotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Thrombotech‘s full profile, request access.

Request a free trial

Thrombotech Patents

  • 28

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • Pending

  • Expiring in next 12 mo

Thrombotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2012014214-A2 Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension Inactive 28-Jul-2010
WO-2012014214-A3 Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension Inactive 28-Jul-2010
WO-2011086557-A1 Peptides for the treatment of respiratory diseases Inactive 13-Jan-2010
EP-2173371-A1 Peptides derived from plasminogen activator inhibitor-1 and uses thereof Active 24-Jul-2007
EP-2173371-B1 Peptides derived from plasminogen activator inhibitor-1 and uses thereof Inactive 24-Jul-2007 C07K14/8132
To view Thrombotech’s complete patent history, request access »

Thrombotech Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Thrombotech‘s full profile, request access.

Request a free trial

Thrombotech FAQs

  • When was Thrombotech founded?

    Thrombotech was founded in 2000.

  • Where is Thrombotech headquartered?

    Thrombotech is headquartered in Ness Ziona, Israel.

  • What industry is Thrombotech in?

    Thrombotech’s primary industry is Drug Discovery.

  • Is Thrombotech a private or public company?

    Thrombotech is a Private company.

  • What is Thrombotech’s current revenue?

    The current revenue for Thrombotech is .

  • How much funding has Thrombotech raised over time?

    Thrombotech has raised $1.4M.

  • Who are Thrombotech’s investors?

    Clal Biotechnology Industries, Hadasit Bio-Holdings, Technomark Life Sciences, and XT Group have invested in Thrombotech.

  • When was Thrombotech acquired?

    Thrombotech was acquired on 24-Jul-2012.

  • Who acquired Thrombotech?

    Thrombotech was acquired by D-Pharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process